cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1257Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПароксизмальные формы фибрилляции предсердий: выбор купирующей терапииParoxysmal atrial fibrillation: treatment choiceТатарскийБ. А.TatarskyB. A.btat@mail.ruНИИ кардиологии имени В.А.Алмазова Росздрава, Санкт-ПетербургV.A. Almazov Research Institute of Cardiology, State Federal Agency for Health and Social Development. St. Petersburg200720062007638289Copyright © Татарский Б.А., 20072007Татарский Б.А.Tatarsky B.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1257

Представлены характеристика и классификация различных вариантов пароксизмальных форм фибрилляции предсердий (ФП). Приводятся основные показания к восстановлению синусового ритма. Дана характеристика основных препаратов, используемых при купировании ФП. Рассматривается вопрос выбора конкретного антиаритмического препарата, подчеркивается необходимость индивидуального подхода при определении тактики лечения.

Characteristics and classification of various paroxysmal atrial fibrillation (AF) forms are presented. Main indications for sinus rhythm restoration are listed, together with characteristics of principal medications used for AF management. Antiarrhythmic choice issue is discussed, with emphasis on individual approaches in choosing treat ment tactics.

фибрилляция предсердийфармакологическая кардиоверсияэффективность и безопасность антиаритмической терапииatrial fibrillationpharmaceutical cardioversionantiarrhythmic therapy effectiveness and safetyReferencesKannel W, Wolf P, Benjamin E, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9.Kannel W, Wolf P, Benjamin E, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9.Benajmim E, Levy D, Vaziri S, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 171: 840-4.Benajmim E, Levy D, Vaziri S, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 171: 840-4.Reiffel J, Curtis A. Antiarrhythmic Drugs. ACCSAP, Book 4. JACC 2005; 15-53.Reiffel J, Curtis A. Antiarrhythmic Drugs. ACCSAP, Book 4. JACC 2005; 15-53.ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. Circulation 2006; 114: 700-52.ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. Circulation 2006; 114: 700-52.Miller J, Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W.B.Saunders company 2001; 731-6.Miller J, Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W.B.Saunders company 2001; 731-6.Татарский Б.А. Бессимптомная форма фибрилляции предсердий. Серд недостат 2002; 5: 217-21.Татарский Б.А. Бессимптомная форма фибрилляции предсердий. Серд недостат 2002; 5: 217-21.Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 87: 121-8.Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 87: 121-8.Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the nitial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-96.Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the nitial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-96.Сулимов В.А. Медикаментозная терапия фибрилляции предсердий: настоящее и будущее. Кардиология 1999; 7: 69-75.Сулимов В.А. Медикаментозная терапия фибрилляции предсердий: настоящее и будущее. Кардиология 1999; 7: 69-75.Wijffels M, Kirchhof C, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.Wijffels M, Kirchhof C, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-26.Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-26.Slavik R, Tisdale J, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001; 44: 121-52.Slavik R, Tisdale J, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001; 44: 121-52.Hohnloser S, Kuch K, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) – a randomised trial. Lancet 2000; 356: 1789-94.Hohnloser S, Kuch K, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) – a randomised trial. Lancet 2000; 356: 1789-94.Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. JACC 2003; 41:1690-6.Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. JACC 2003; 41:1690-6.Wyse D, Waldo A, DiMarco J, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.Wyse D, Waldo A, DiMarco J, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.Pelargonio G, Prystowsky E. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract Cardiovasc Med 2005; 2: 514-21.Pelargonio G, Prystowsky E. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract Cardiovasc Med 2005; 2: 514-21.Prystowsky E, Benson D, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the ubcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-77.Prystowsky E, Benson D, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the ubcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-77.Camm J, Haffajee C, Sheldon R, et al. International Consensus Roundtable on Atrial Fibrillation. Cardiol Rev 2000;17(Suppl): 1- 19.Camm J, Haffajee C, Sheldon R, et al. International Consensus Roundtable on Atrial Fibrillation. Cardiol Rev 2000;17(Suppl): 1- 19.Capucci A, Villani GQ, Piepoli MF. Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. Am J Cardiol 2003; 92: 1345-7.Capucci A, Villani GQ, Piepoli MF. Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. Am J Cardiol 2003; 92: 1345-7.Lenzi T, Boriani G, Botto G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70: 69-72.Lenzi T, Boriani G, Botto G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70: 69-72.Татарский Б.А. Стратегия «таблетка в кармане» при купировании фибрилляции предсердий. РКЖ 2005; 1: 45-54.Татарский Б.А. Стратегия «таблетка в кармане» при купировании фибрилляции предсердий. РКЖ 2005; 1: 45-54.Фомина И.Г., Таризманова А.И., Ветлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваск тер профил 2005; 4: 65-9.Фомина И.Г., Таризманова А.И., Ветлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваск тер профил 2005; 4: 65-9.Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000; 85: 3-11.Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000; 85: 3-11.Li H, Natale A, Tomassoni G, et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardio 1999; 84: 1096-8, A10.Li H, Natale A, Tomassoni G, et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardio 1999; 84: 1096-8, A10.Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004; 25: 1318-24.Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004; 25: 1318-24.Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89: 239-48.Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89: 239-48.Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (European and Australian Multicenter Evaluative Research on atrial fibrillation Dofetilide) Study. Circulation 1998; 98: 1633-9.Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (European and Australian Multicenter Evaluative Research on atrial fibrillation Dofetilide) Study. Circulation 1998; 98: 1633-9.Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-90.Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-90.UK Propafenone PSVT Study Group. A randomized, placebocontrolled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550-7.UK Propafenone PSVT Study Group. A randomized, placebocontrolled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550-7.Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of atrial fibrillation: a placebo-controlled study. JACC 1996; 28: 700-6.Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of atrial fibrillation: a placebo-controlled study. JACC 1996; 28: 700-6.

The authors declare that there are no conflicts of interest present.